STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a new two-drug combination (sapanisertib and osimertinib) in 36 adults with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatment. The main goal is to find the safest dose and identify side effects. This is …
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or can't be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the drug combo can shrink tum…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
Targeted pill after lung cancer surgery shows promise in extending life
Disease control OngoingThis study tests whether taking erlotinib (a daily pill that blocks cancer growth signals) after surgery helps people with a specific type of lung cancer (EGFR-mutant) live longer compared to just watching and waiting. About 390 adults with early-stage lung cancer that was fully …
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC
-
Massive lung cancer study aims to match patients with precision treatments
Knowledge-focused OngoingThis study screens up to 8300 people with early-stage non-small cell lung cancer (stages IB to IIIA) whose tumor has been or will be removed by surgery. Researchers analyze the tumor's genes to find specific mutations, which helps doctors choose the most effective targeted therap…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 17, 2026 03:11 UTC